A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 in Hypertensive Men (MK-8266-002)

Summary

This study evaluated adverse events (AEs), study discontinuation due to AEs, and pharmacodynamics of MK-8266 in male participants with mild to moderate hypertension.

Timeline

Start

2010-03-01

Primary completion

2010-11-01

Completion

2010-11-01

Outcome

Mixed primary results

registry analysis (other test); Panel B: MK-8266 BID, 1.8 mg vs Pooled Placebo; p = 0.0224; Mean Difference (Final Values) -13.1 (90% CI -23.7 to -2.48) NCT01096160 ↗

registry analysis (other test); Panel A: MK-8266 BID, 1 mg vs Pooled Placebo; p = 0.1194; Mean Difference (Final Values) -7.08 (90% CI -17.1 to 2.92) NCT01096160 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MK-8266	Unknown	1 mg	Oral
Subject	MK-8266	Unknown	1.8 mg	Oral
Subject	MK-8266	Unknown	2.4 mg	Oral

Indications